Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,533 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,899 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05351424 | AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc(ADELANTE) | recruiting | N/A | 194 | Columbia UniversityOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06335914 | Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer | recruiting | N/A | 30 | University Health Network, TorontoOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07407608 | ABlative Radiotherapy (for) Unfavorable Prostate Tumors 2.0(ABRUPT 2) | recruiting | — | 58 | University of Milano BicoccaOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT04704505 | Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)(BAT-RAD) | recruiting | Phase 2 | 47 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 2 | Feb 6, 2026 | clinicaltrials |
| NCT07391982 | Dose De-escalation in Prostate Radiotherapy Using an MR-Linac in Two Fractions(DESTINATION 2) | recruiting | N/A | 54 | The Netherlands Cancer InstituteOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT06547398 | Prostate Adaptive Radiation Therapy | recruiting | N/A | 130 | Royal North Shore HospitalOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06591819 | Hypofractionated WPPT With HDR Boost | recruiting | Phase 2 | 30 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06631521 | Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer | recruiting | Phase 1 | 30 | AdventHealthOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07001241 | Telehealth Exercise Program Evaluating Fatigue and Physical Function in Rural Cancer Survivors | recruiting | Phase 2 | 134 | University of Colorado, DenverOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07276438 | Image-Guidance and Online Adaptation With Stereotactic Body Radiation Therapy for the Treatment of Localized Prostate Cancer, MANTICORE Trial | recruiting | N/A | 186 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07325721 | Hypofractionated Radiotherapy With a Focal Microboost for High-Risk and Locally Advanced Prostate Cancer | recruiting | Phase 2 | 46 | Medical University of South CarolinaOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07389512 | Pharmaceutical Management in Targeted Radioligand Therapy(PharmTRT) | recruiting | — | 600 | Hospices Civils de LyonOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT02099734 | Germ Cell Tumor and Testicular Tumor DNA Registry | recruiting | — | 1,000 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT04729114 | A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer | recruiting | Phase 1 | 174 | Astellas Pharma Global Development, Inc.INDUSTRY | 2 | Feb 4, 2026 | clinicaltrials |
| NCT05810467 | The Active Surveillance Study(AS) | recruiting | — | 200 | Institute of Cancer Research, United KingdomOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06408298 | HCQ in Resectable Localized Prostate Cancer | recruiting | Early Phase 1 | 20 | Lionel.D.Lewis, MDOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06563388 | Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial(ID-COMET) | recruiting | Phase 3 | 800 | Roswell Park Cancer InstituteOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06636526 | The i4i PRODICT® Study: Evaluation of the i4i PRODICT® Test in Different Ethnic Groups (The i4i PRODICT® Study). | recruiting | — | 1,000 | Institute of Cancer Research, United KingdomOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07335224 | Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture(MPOWER) | recruiting | N/A | 24 | Inova Health Care ServicesOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07209176 | Physician- and Patient-based Barriers to NGS Testing | recruiting | N/A | 256 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT06200974 | Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer(BrachyTRACKS) | recruiting | — | 100 | British Columbia Cancer AgencyOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06705803 | Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE) | recruiting | — | 3,000 | University of ChicagoOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06941363 | Salvage Ultrahypofractionated Postoperative External Radiotherapy For Biochemical Recurrence(SUPERB) | recruiting | — | 50 | University of Milano BicoccaOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07344363 | Prostate Cancer REsearch Using Cross-validation of Innovative Sampling, Integrating LC-MS/MS for Optimized Therapeutic Drug moNitoring(PRECISION) | recruiting | — | 100 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06700057 | Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.(DOSIPROSTATE) | recruiting | — | 50 | Institut BergoniéOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT06719206 | Reduce Sedentary Behavior During Cancer Treatment - the RedSedCan Study(RedSedCan) | recruiting | N/A | 172 | Mälardalen UniversityOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07243834 | Assessing a Digital Exercise Intervention for Health Outcomes and Engagement in Regular Exercise(ADHERE) | recruiting | N/A | 160 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT03322891 | Improving Health Literacy in African-American Prostate Cancer Patients | recruiting | N/A | 210 | Emory UniversityOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05806515 | Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation | recruiting | Phase 2 | 44 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05864196 | Two Fraction Prostate SBRT With DIL SIB | recruiting | Phase 1 | 80 | NYU Langone HealthOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT06099093 | Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan | recruiting | Phase 4 | 30 | Brigham and Women's HospitalOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT06842264 | The Development and Validation of MRI-AI-based Predictive Models for csPCa | recruiting | — | 3,000 | Peking University First HospitalOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT04734730 | Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer | recruiting | Phase 2 | 70 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06371768 | Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors(AYA STEPS) | recruiting | N/A | 260 | Duke UniversityOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06397703 | ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer | recruiting | Phase 2 | 392 | NYU Langone HealthOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07210086 | Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R) | recruiting | Phase 2 | 50 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06636123 | GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy | recruiting | Phase 1 | 30 | Virginia Commonwealth UniversityOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07370597 | LUtetium-177 DOsimetry as a Predictive Biomarker of Response in Metastatic Prostate Cancer Patients Treated With PSMA Radioligand THerapy.(LUDOPATH) | recruiting | — | 110 | Jules Bordet InstituteOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT04402151 | Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer(PSMA SBRT-SIB) | recruiting | Phase 2 | 50 | Weill Medical College of Cornell UniversityOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07363382 | The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer | recruiting | Phase 1 / Phase 2 | 6 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07363486 | Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 9 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07358806 | Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 51 | Oscotec Inc.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07291414 | A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients | recruiting | N/A | 80 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07343349 | Addition of Focal Boost to Primary Radiotherapy for Prostate Cancer in 12 or 20 Fractions(DAPROCA10) | recruiting | N/A | 1,016 | Rigshospitalet, DenmarkOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05366881 | cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease(CAMPERR) | recruiting | — | 7,000 | Adela, IncINDUSTRY | 1 | Jan 20, 2026 | clinicaltrials |
| NCT07351461 | Anxiety in Patients Under Active Surveillance for Localized Prostate Cancer and Their Partners.(ANCAPRO) | recruiting | — | 432 | University Hospital, LilleOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05038332 | Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT]) | recruiting | Phase 2 | 136 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT05264337 | Lymphedema After Urologic Surgery | recruiting | — | 400 | Vastra Gotaland RegionOTHER_GOV | 1 | Jan 16, 2026 | clinicaltrials |
| NCT06406803 | The Impact of Physical Activity Versus Dietary Energy Restriction on Tumour and Muscle Protein Synthesis in Prostate Cancer Patients(DIRECT) | recruiting | N/A | 45 | Maastricht University Medical CenterOTHER | 1 | Jan 16, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Feb 12, 2026source: clinicaltrials